Patient Reported Outcomes in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

Background: Introduction Alopecia areata (AA) is a serious autoimmune disease, characterized by patchy or complete hair loss on the scalp and/or body. THRIVE-AA1 is a double-blind, placebo-controlled Phase 3 trial with CTP-543, an oral JAK1/JAK2 Inhibitor for treatment of AA. Material and Methods Eligible AA patients were 18-65 years with 2:50% scalp hair loss and current AA episode >6 months and <10 years.